by John Conrad | Dec 12, 2024 | Member News, NewsBrief
In a significant move addressing one of healthcare’s most pressing challenges, Meitheal Pharmaceuticals has secured exclusive U.S. commercial rights to XENLETA® (lefamulin acetate). The timing couldn’t be more critical: between now and 2050, antibiotic...
by John Conrad | Jul 19, 2024 | NewsBrief
In a strategic move to expand its specialty biopharmaceuticals portfolio, Meitheal Pharmaceuticals has acquired the North American rights to CONTEPO™ (fosfomycin for injection) from Nabriva Therapeutics. The announcement, made on July 18, 2024, marks a significant...
by John Conrad | Jun 28, 2024 | NewsBrief
Meitheal Pharmaceuticals, a Chicago-based biopharmaceutical company, has made a significant move in the biosimilars market by acquiring exclusive U.S. commercial rights to YUSIMRY® (adalimumab-aqvh), a biosimilar of the widely-used drug Humira®. This strategic...
by John Conrad | Jun 13, 2024 | NewsBrief
Meitheal Pharmaceuticals, a Chicago-based pharmaceutical company, has been named the second fastest growing company on Crain’s Fast 50 list. The company recorded an impressive 13,294.6% growth rate, with over $230 million in revenue and a total of 90 employees,...
